Christian Fellowes

Christian Fellowes is an Investment Director on the Healthcare and Life Sciences team at Inflexion Private Equity, a large UK mid-market private equity firm. He brings an unusual combination of medical, transaction, and entrepreneurial experience to healthcare dealmaking. He qualified in medicine at Imperial College London, earning a BSc in cardiovascular science (2006) and an MBBS, and was awarded multiple academic prizes during his studies. He began his career as a practising doctor in major London teaching hospitals, including Hammersmith Hospital and St Mary's Hospital.

Fellowes then moved into finance, joining KPMG's Corporate Finance and Transaction Services division, where he qualified as a chartered accountant. He subsequently built a career in healthcare private equity, holding investment roles at Duke Street and then GHO Capital Partners — the London-based specialist healthcare investment adviser — where he covered a range of healthcare subsectors including pharmaceuticals, medical devices, and diagnostics. (The stub profile reflects this GHO Capital chapter; he has since moved to Inflexion.)

He is also an entrepreneur, having co-founded ASep Healthcare Limited, a medical technology company set up to commercialise a medical product he developed with a colleague. At Inflexion he now spends most of his time partnering with ambitious management teams in the pharma services / pharma outsourcing space.

Note on the stub data: GHO Capital is a healthcare private equity firm managing multi-billion-euro funds (its Fund IV closed at over €2.5 billion in 2025), and Inflexion runs funds in the billions of pounds. The stub's "Angel Investors / Seed Round / Vice President" descriptors do not match either firm's actual profile or Fellowes' real role; his work is institutional healthcare private equity, not angel/seed investing.

• Invests in healthcare and life-sciences businesses, with particular depth in pharma services / pharma outsourcing (CDMOs/CROs), specialty pharmaceuticals, medical devices, and diagnostics.
• Operates at the growth-equity / buyout end of the market (Inflexion typically backs established, growing companies, often alongside founders and management), not at seed/angel stage.
• Values a clinical + commercial lens — his medical training and CDMO/pharma-services focus mean he evaluates companies on both scientific/regulatory credibility and commercial scalability.
• In his own words on joining Inflexion, he cited being "attracted by the people and opportunity to leverage this differentiation internationally," pointing to a thesis of backing management teams and helping them expand internationally using the firm's portfolio-support infrastructure.